Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.

T cell receptor-therapy in HBV-related hepatocellularcarcinoma.

BRUNETTO, MAURIZIA ROSSANA;BONINO, FERRUCCIO;
2015-01-01

Abstract

Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.
2015
Bertoletti, A; Brunetto, MAURIZIA ROSSANA; Maini, Mk; Bonino, Ferruccio; Qasim, W; Stauss, H.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/755856
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 26
social impact